Buie T, Campbell DB, Fuchs GJ 3rd, Furuta GT, Levy J, Vandewater J, Whitaker AH, Atkins D, Bauman ML, Beaudet AL, Carr EG, Gershon MD, Hyman SL, Jirapinyo P, Jyonouchi H, Kooros K, Kushak R, Levitt P, Levy SE, Lewis JD, Murray KF, Natowicz MR, Sabra A, Wershil BK, Weston SC, Zeltzer L, Winter H
Diabetes 5 , e173e173 (2015)
Third, energy delivery, radiofrequency, ultrasound, laser, or intense pulsed light that injures the dermis in a controlled way, triggering collagen and elastin remodeling over the following 12 weeks
Zealand does not currently have a disclosed clinical-stage triple agonist, which means its IP position is ahead of its product position